List of works - Bimal K. Chakrabarti

A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial

scientific article

An efficiently cleaved HIV-1 clade C Env selectively binds to neutralizing antibodies

scientific article

Anti-HIV B Cell lines as candidate vaccine biosensors

scientific article published on 12 October 2012

Association of mutations in V3/C3 domain with enhanced sensitivity of HIV-1 clade C primary envelopes to autologous broadly neutralizing plasma antibodies

scientific article published on 15 June 2016

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

scientific article

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals

scientific article

Cell surface ectodomain integrity of a subset of functional HIV-1 envelopes is dependent on a conserved hydrophilic domain containing region in their C-terminal tail

scientific article published on 20 July 2018

Comparative Neutralization Sensitivity of Indian and South African HIV-1 Clade C Viruses to Plasma Antibodies from Chronically Infected Indian Donors

article

Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop

scientific article published on 13 January 2016

Correction for Chakrabarti et al., Robust Neutralizing Antibodies Elicited by HIV-1 JRFL Envelope Glycoprotein Trimers in Nonhuman Primates.

scientific article published on 16 December 2014

Correction: Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability

scientific article published on 24 May 2016

Determinants in V2C2 region of HIV-1 clade C primary envelopes conferred altered neutralization susceptibilities to IgG1b12 and PG9 monoclonal antibodies in a context-dependent manner

scientific article published on 5 July 2014

Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity

scientific article published on 8 June 2011

Effects of Antigen and Genetic Adjuvants on Immune Responses to Human Immunodeficiency Virus DNA Vaccines in Mice ⬇️

scientific article published on January 1, 2002

Elicitation of simian immunodeficiency virus-specific cytotoxic T lymphocytes in mucosal compartments of rhesus monkeys by systemic vaccination

scientific article

Engineered mice and B cell lines expressing broadly neutralizing antibodies and their unmutated precursors: tools for HIV vaccinology.

scientific article published on 13 September 2012

Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system

scientific article

Envelope proteins of two HIV-1 clades induced different epitope-specific antibody response

scientific article published on 8 February 2018

Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate

scientific article

Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies

scientific article published on 15 October 2008

HIV Type 1 Env Precursor Cleavage State Affects Recognition by Both Neutralizing and Nonneutralizing gp41 Antibodies ⬇️

scientific article published on January 19, 2011

HIV-1 Neutralizing Antibodies Display Dual Recognition of the Primary and Coreceptor Binding Sites and Preferential Binding to Fully Cleaved Envelope Glycoproteins ⬇️

scientific article published on August 8, 2012

HIV-1 neutralizing antibodies display dual specificity for the primary and coreceptor binding sites and preferential recognition of fully-cleaved Env.

scientific article published on 13 September 2012

Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys

scientific article

Identification and characterization of a naturally occurring, efficiently cleaved, membrane-bound, clade A HIV-1 Env, suitable for immunogen design, with properties comparable to membrane-bound BG505.

scientific article published on 6 July 2017

Immunogenicity of Multiple Gene and Clade Human Immunodeficiency Virus Type 1 DNA Vaccines ⬇️

scientific article published on December 1, 2003

Ligand accessibility to the HIV-1 Env co-receptor binding site can occur prior to CD4 engagement and is independent of viral tier category.

scientific article published on 20 April 2018

Lysis of human immunodeficiency virus type 1 by a specific secreted human phospholipase A2

scientific article published on 8 November 2006

Membrane bound modified form of clade B Env, JRCSF is suitable for immunogen design as it is efficiently cleaved and displays all the broadly neutralizing epitopes including V2 and C2 domain-dependent conformational epitopes.

scientific article published on 21 November 2016

Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization

scientific article

Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys

scientific article

Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins

scientific article published on January 2005

P05-07. Evaluation of peripheral and bone marrow B cell responses in rhesus macaques after immunization with soluble HIV-1 gp140 trimers.

scientific article

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine

scientific article published on 8 November 2006

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector

scientific article published on 8 November 2006

Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines

scientific article

Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys

scientific article published on June 2006

Priming with DNA encoding functional trimers and boosting with soluble trimeric protein elicited tier 2 neutralizing antibodies in non-human primates

scientific article published on 13 September 2012

Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates

scientific article

Robust neutralizing antibodies elicited by HIV-1 JRFL envelope glycoprotein trimers in nonhuman primates

scientific article published on 25 September 2013

Selective Modification of Variable Loops Alters Tropism and Enhances Immunogenicity of Human Immunodeficiency Virus Type 1 Envelope.

scientific article published in April 2006

Selective expansion of HIV-1 envelope glycoprotein-specific B cell subsets recognizing distinct structural elements following immunization

scientific article

Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope

scientific article published on April 2004

Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates

scientific article

Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates

Stabilization of a soluble, native-like trimeric form of an efficiently cleaved Indian HIV-1 clade C envelope glycoprotein

scientific article published on 10 March 2017

Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site

scientific article (publication date: May 2009)

Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability

scientific article

Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site

scientific article

List of works by Bimal K. Chakrabarti

A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial

An efficiently cleaved HIV-1 clade C Env selectively binds to neutralizing antibodies

Anti-HIV B Cell lines as candidate vaccine biosensors

Association of mutations in V3/C3 domain with enhanced sensitivity of HIV-1 clade C primary envelopes to autologous broadly neutralizing plasma antibodies

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals

Cell surface ectodomain integrity of a subset of functional HIV-1 envelopes is dependent on a conserved hydrophilic domain containing region in their C-terminal tail

Comparative Neutralization Sensitivity of Indian and South African HIV-1 Clade C Viruses to Plasma Antibodies from Chronically Infected Indian Donors

Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop

Correction for Chakrabarti et al., Robust Neutralizing Antibodies Elicited by HIV-1 JRFL Envelope Glycoprotein Trimers in Nonhuman Primates.

Correction: Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability

Determinants in V2C2 region of HIV-1 clade C primary envelopes conferred altered neutralization susceptibilities to IgG1b12 and PG9 monoclonal antibodies in a context-dependent manner

Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity

Effects of Antigen and Genetic Adjuvants on Immune Responses to Human Immunodeficiency Virus DNA Vaccines in Mice ⬇️

Elicitation of simian immunodeficiency virus-specific cytotoxic T lymphocytes in mucosal compartments of rhesus monkeys by systemic vaccination

Engineered mice and B cell lines expressing broadly neutralizing antibodies and their unmutated precursors: tools for HIV vaccinology.

Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system

Envelope proteins of two HIV-1 clades induced different epitope-specific antibody response

Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate

Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies

HIV Type 1 Env Precursor Cleavage State Affects Recognition by Both Neutralizing and Nonneutralizing gp41 Antibodies ⬇️

HIV-1 Neutralizing Antibodies Display Dual Recognition of the Primary and Coreceptor Binding Sites and Preferential Binding to Fully Cleaved Envelope Glycoproteins ⬇️

HIV-1 neutralizing antibodies display dual specificity for the primary and coreceptor binding sites and preferential recognition of fully-cleaved Env.

Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys

Identification and characterization of a naturally occurring, efficiently cleaved, membrane-bound, clade A HIV-1 Env, suitable for immunogen design, with properties comparable to membrane-bound BG505.

Immunogenicity of Multiple Gene and Clade Human Immunodeficiency Virus Type 1 DNA Vaccines ⬇️

Ligand accessibility to the HIV-1 Env co-receptor binding site can occur prior to CD4 engagement and is independent of viral tier category.

Lysis of human immunodeficiency virus type 1 by a specific secreted human phospholipase A2

Membrane bound modified form of clade B Env, JRCSF is suitable for immunogen design as it is efficiently cleaved and displays all the broadly neutralizing epitopes including V2 and C2 domain-dependent conformational epitopes.

Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization

Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys

Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins

P05-07. Evaluation of peripheral and bone marrow B cell responses in rhesus macaques after immunization with soluble HIV-1 gp140 trimers.

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector

Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines

Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys

Priming with DNA encoding functional trimers and boosting with soluble trimeric protein elicited tier 2 neutralizing antibodies in non-human primates

Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates

Robust neutralizing antibodies elicited by HIV-1 JRFL envelope glycoprotein trimers in nonhuman primates

Selective Modification of Variable Loops Alters Tropism and Enhances Immunogenicity of Human Immunodeficiency Virus Type 1 Envelope.

Selective expansion of HIV-1 envelope glycoprotein-specific B cell subsets recognizing distinct structural elements following immunization

Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope

Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates

Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates

Stabilization of a soluble, native-like trimeric form of an efficiently cleaved Indian HIV-1 clade C envelope glycoprotein

Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site

Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability

Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site